These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 31106085)
1. A Review of Novel Antidepressants: A Guide for Clinicians. Faquih AE; Memon RI; Hafeez H; Zeshan M; Naveed S Cureus; 2019 Mar; 11(3):e4185. PubMed ID: 31106085 [TBL] [Abstract][Full Text] [Related]
2. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. McIntyre RS Neuropsychiatr Dis Treat; 2017; 13():2913-2919. PubMed ID: 29238196 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. Wagner G; Schultes MT; Titscher V; Teufer B; Klerings I; Gartlehner G J Affect Disord; 2018 Mar; 228():1-12. PubMed ID: 29197738 [TBL] [Abstract][Full Text] [Related]
4. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. Behlke LM; Lenze EJ; Carney RM CNS Drugs; 2020 Nov; 34(11):1133-1147. PubMed ID: 33064291 [TBL] [Abstract][Full Text] [Related]
5. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Deardorff WJ; Grossberg GT Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953 [TBL] [Abstract][Full Text] [Related]
7. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Schwartz TL; Siddiqui UA; Stahl SM Ther Adv Psychopharmacol; 2011 Jun; 1(3):81-7. PubMed ID: 23983930 [TBL] [Abstract][Full Text] [Related]
8. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Palmer EC; Binns LN; Carey H Ann Pharmacother; 2014 Aug; 48(8):1030-1039. PubMed ID: 24811398 [TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo. Bundgaard C; Eneberg E; Sánchez C Neuropharmacology; 2016 Apr; 103():104-11. PubMed ID: 26700248 [TBL] [Abstract][Full Text] [Related]
10. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. Köhler S; Cierpinsky K; Kronenberg G; Adli M J Psychopharmacol; 2016 Jan; 30(1):13-22. PubMed ID: 26464458 [TBL] [Abstract][Full Text] [Related]
11. Levomilnacipran: More of the Same? Gautam M; Kaur M; Jagtap P; Krayem B Prim Care Companion CNS Disord; 2019 Sep; 21(5):. PubMed ID: 31509357 [TBL] [Abstract][Full Text] [Related]
12. Risk of QT/QTc prolongation among newer non-SSRI antidepressants. Jasiak NM; Bostwick JR Ann Pharmacother; 2014 Dec; 48(12):1620-8. PubMed ID: 25204465 [TBL] [Abstract][Full Text] [Related]
13. Drug-drug interactions involving antidepressants: focus on desvenlafaxine. Low Y; Setia S; Lima G Neuropsychiatr Dis Treat; 2018; 14():567-580. PubMed ID: 29497300 [TBL] [Abstract][Full Text] [Related]
14. Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression. Rickels K; Athanasiou M; Reed C Per Med; 2009 Mar; 6(2):217-224. PubMed ID: 29788607 [TBL] [Abstract][Full Text] [Related]
15. [Mechanism of action of antidepressants and therapeutic perspectives]. Bourin M; David DJ; Jolliet P; Gardier A Therapie; 2002; 57(4):385-96. PubMed ID: 12422559 [TBL] [Abstract][Full Text] [Related]
17. Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action. Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU Psychiatry Investig; 2015 Apr; 12(2):155-63. PubMed ID: 25866514 [TBL] [Abstract][Full Text] [Related]
18. The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. Fasipe OJ IBRO Rep; 2019 Jun; 6():95-110. PubMed ID: 31211282 [TBL] [Abstract][Full Text] [Related]
19. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. Zimmerman M; Clark HL; Multach MD; Walsh E; Rosenstein LK; Gazarian D J Affect Disord; 2016 Jan; 190():357-361. PubMed ID: 26546771 [TBL] [Abstract][Full Text] [Related]